Bivalent Covid-19 vaccines approved

Thursday 1 September 2022

The US Food and Drug Administration has approved two new bivalent vaccines to protect against Covid-19. They are to be administered as an updated single booster dose at least two months after primary or booster vaccination. The decisions were taken in response to the prevalence of the omicron variant of the SARS-CoV-2 virus and specifically to its two new subvariants BA.4 and BA.5.